- Home
- PRPL vs RVPH Comparison
PRPL vs RVPH Comparison
Compare PRPL & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- RVPH
- Stock Information
- Founded
- PRPL 2010
- RVPH 2006
- Country
- PRPL United States
- RVPH United States
- Employees
- PRPL N/A
- RVPH N/A
- Industry
- PRPL Home Furnishings
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- RVPH Health Care
- Exchange
- PRPL Nasdaq
- RVPH Nasdaq
- Market Cap
- PRPL 96.8M
- RVPH 32.8M
- IPO Year
- PRPL N/A
- RVPH N/A
- Fundamental
- Price
- PRPL $0.75
- RVPH $0.36
- Analyst Decision
- PRPL Hold
- RVPH Strong Buy
- Analyst Count
- PRPL 2
- RVPH 5
- Target Price
- PRPL $1.25
- RVPH $9.00
- AVG Volume (30 Days)
- PRPL 674.8K
- RVPH 2.4M
- Earning Date
- PRPL 08-04-2025
- RVPH 08-13-2025
- Dividend Yield
- PRPL N/A
- RVPH N/A
- EPS Growth
- PRPL N/A
- RVPH N/A
- EPS
- PRPL N/A
- RVPH N/A
- Revenue
- PRPL $472,015,000.00
- RVPH N/A
- Revenue This Year
- PRPL N/A
- RVPH N/A
- Revenue Next Year
- PRPL $10.65
- RVPH N/A
- P/E Ratio
- PRPL N/A
- RVPH N/A
- Revenue Growth
- PRPL N/A
- RVPH N/A
- 52 Week Low
- PRPL $0.56
- RVPH $0.30
- 52 Week High
- PRPL $1.50
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- PRPL 45.25
- RVPH 29.52
- Support Level
- PRPL $0.71
- RVPH $0.30
- Resistance Level
- PRPL $0.82
- RVPH $0.83
- Average True Range (ATR)
- PRPL 0.05
- RVPH 0.07
- MACD
- PRPL -0.00
- RVPH -0.04
- Stochastic Oscillator
- PRPL 21.61
- RVPH 11.25
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.